Marker Therapeutics, Inc.

Monthly Archives: September 2014

TapImmune CEO Provides Update on Corporate Activity and Progression of Clinical Programs

…I am pleased to provide this update to existing shareholders and interested potential shareholders

SEATTLE–(BUSINESS WIRE)–

TapImmune is a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and infectious disease. The company now has multiple clinical trials underway at the Mayo Clinic in Rochester, MN, as well as an infectious disease program also completing pre-clinical testing at Mayo for a novel smallpox vaccine.

Read More

TapImmune Releases Positive Interim Data on Phase I Clinical Trial of Folate Receptor Alpha Antigens in Ovarian and Breast Cancer

…All Patients Developed Immune Responses as All Five Peptides Shown to be Immunogenic

SEATTLE–(BUSINESS WIRE)–TapImmune Inc. (OTCQB:TPIV) is extremely pleased to report that analysis of the interim data from the first 13 patients in a Phase I clinical trial show that each of the patients treated have raised specific T-cell immune responses against a set of 5 naturally processed folate receptor alpha Class II antigenic epitopes.

Read More

TapImmune Inc to Present at SeeThruEquity Microcap Conference

…Seattle, WA / ACCESSWIRE / September 4, 2014 / TapImmune, Inc. (TPIV), announces that company executives will attend and present at the SeeThruEquity Microcap Investor Conference to be held Thursday September 11th at the Convene Times Square, New York City. The presentation is scheduled for 10:00AM ET.

Company executives will provide an overview of TapImmune’s development of the most comprehensive and innovative immunotherapeutics in cancer and infectious diseases and latest corporate news.

Read More

TapImmune Inc to Present at 16th Annual Rodman & Renshaw Healthcare Conference

…Seattle WA / ACCESSWIRE / September 3, 2014 / TapImmune, Inc. (TPIV), a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease, will be featured as a presenting company at the 16th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C.

Read More